|Day's Range||62.17 - 62.63|
|52 Week Range||45.28 - 62.63|
|PE Ratio (TTM)||36.31|
|Earnings Date||Aug 1, 2017 - Aug 7, 2017|
|Dividend & Yield||0.42 (0.68%)|
|1y Target Est||62.62|
Zoetis Inc. will participate in the Stifel 2017 Dental and Veterinary Conference on Wednesday, May 31, 2017, in New York, N.Y. Kristin Peck, Executive Vice President and President, U.S.
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.